Early clinical Custom Pharma Services specializes in pre-clinical formulation development, solubilisation and early clinical material manufacturing, presenting a clear opportunity to engage for CRO/CDMO services during phase transitions.

Oral Solid Focus With a strong emphasis on oral solid dosage forms, including highly potent drugs and poorly bioavailable compounds, there is potential to upsell formulation optimisation, process development and scale-up services for niche therapeutic areas.

Orphan & HP Capabilities in orphan drug development and containment for highly potent APIs position the company to pursue collaborations on specialty programs that require tight regulatory/compliance controls and specialized manufacturing know-how.

Clinical to Commercial End-to-end service offering from development through commercial manufacturing allows cross-sell to customers seeking continuity, reducing vendor switching risk and increasing contract value across product lifecycles.

Strategic Partnerships Partnership approach and molecule-first mindset, plus recent collaborative activity in Covid-19 related efforts, indicate openness to co-development agreements, strategic alliances, and joint funding opportunities with academic or biotech partners.